Clinical Trials Logo

Arthritis clinical trials

View clinical trials related to Arthritis.

Filter by:

NCT ID: NCT00162279 Completed - Clinical trials for Rheumatoid Arthritis

The Study of Abatacept in Combination With Etanercept

Start date: October 2000
Phase: Phase 2
Study type: Interventional

The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

NCT ID: NCT00162266 Completed - Clinical trials for Rheumatoid Arthritis

Abatacept With Methotrexate- Phase IIB

Start date: October 2000
Phase: Phase 2
Study type: Interventional

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

NCT ID: NCT00162201 Completed - Clinical trials for Rheumatoid Arthritis

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy

Start date: October 2003
Phase: Phase 1
Study type: Interventional

Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with anti-TNF (tumor necrosing factor)blocking agents.

NCT ID: NCT00160693 Completed - Clinical trials for Rheumatoid Arthritis

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

Start date: March 2003
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.

NCT ID: NCT00160641 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Start date: November 2005
Phase: Phase 3
Study type: Interventional

An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.

NCT ID: NCT00160602 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Start date: June 2005
Phase: Phase 3
Study type: Interventional

A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.

NCT ID: NCT00157872 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Rofecoxib Versus Naproxen in the Treatment of Chinese Patient With Rheumatoid Arthritis (0966-231)

Start date: January 7, 2004
Phase: Phase 4
Study type: Interventional

A study to compare rofecoxib versus naproxen in the treatment of Chinese patients with rheumatoid arthritis.

NCT ID: NCT00154336 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

Start date: July 2004
Phase: Phase 2
Study type: Interventional

Imatinib is a member of a new class of drugs known as signal transduction inhibitors. The purpose of this study is to evaluate the efficacy, safety and tolerability of imatinib in the treatment of rheumatoid arthritis in combination with methotrexate in patients who do not respond satisfactorily to standard treatment, e.g. methotrexate.

NCT ID: NCT00153673 Completed - Arthritis Clinical Trials

Effect of Selective COX-2 Inhibition on Ulcer Healing

Start date: February 2001
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.

NCT ID: NCT00153660 Completed - Clinical trials for Cardiovascular Diseases

Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients

Start date: June 2005
Phase: Phase 3
Study type: Interventional

The aim of this study is to compare celecoxib plus a PPI (esomeprazole) versus naproxen plus a PPI (esomeprazole) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer bleeding who require concomitant ASA. We hypothesized that among patients with a history of ulcer bleeding who require concomitant ASA, celecoxib plus esomprazole would be superior to naproxen plus esomeprazole for the prevention of recurrent ulcer bleeding.